

ACR* Recommendations include MBDA† (Vectra®) as a disease activity measure that meets minimum standards for regular use for patients with rheumatoid arthritis



46 disease activity measures were assessed¹



Only 11 measures met a minimum standard for regular use¹



Vectra is among the 11 disease activity measures that can be used at an RA patient's regular clinical assessment visits¹



Vectra can help assist clinicians with adhering to a treat-to-target approach for the **management of RA**¹



†Multi-Biomarker Disease Activity Score

*© American College of Rheumatology. All Rights Reserved
onlinelibrary.wiley.com/doi/full/10.1002/acr.24042

Copyright © 2000-2019 by John Wiley & Sons, Inc. or related companies. All rights reserved

1. England, B.R., Tiong, B.K., Bergman, M.J., Curtis, J.R., Kazi, S., Mikuls, T.R., O'Dell, J.R., Ranganath, V.K., Limanni, A., Suter, L.G. and Michaud, K. (2019), 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res, 71: 1540-1555. doi:10.1002/acr.24042

Integrate Vectra[®] into Rheumatoid Arthritis Patient Care

1

MANAGEMENT DECISIONS

Patient and provider agree to make a treatment change



Test at baseline and at time of treatment change decision



Therapy Initiation or Change:

Until the desired treatment target is reached drug therapy should be adjusted every 3-6 months

2

THERAPY MONITORING

Evaluate if treatment is working



Test at 3-6 months after treatment change



Primary Goal:

Achieving a state of disease remission in RA is considered a primary treatment goal

3

LOW DISEASE ACTIVITY MONITORING

Evaluate that the patient remains within disease goal



Continue to test patient two times a year



Monitor:

Monitor that patient is remaining in treatment goal